PhI­Ib im­plo­sion punts Imara back to pre­clin­i­cal mode as biotech ax­es pro­grams in sick­le cell dis­ease, be­ta-tha­lassemia

Imara Ther­a­peu­tics is shut­ting down its lead pro­gram in sick­le cell dis­ease and be­ta-tha­lassemia — in­clud­ing a pair of Phase IIb stud­ies — af­ter the lat­est in­ter­im …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER